F-Prime Capital

Tracked participation in 2 Atlas companies, with 1 explicitly attributed lead.

2portfolio companies

3round participations

1lead positions

May 2020latest activity

Conviction

Most recent leads

The latest rounds this investor is sourced as leading, newest first.

Mar 2019OwkinSeries A (venture round / extension)Undisclosed

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

OOwkinScienceOwkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical…$1Bvaluation$635.2MraisedRecent roundsTotal disclosed (company press kit aggregate) · null$304.1M · Bpifrance Large Ventures, Bristol-Myers Squibb +10Spin-out financing: Waiv (formerly Owkin Dx) · Mar 2026$33M · led by Alpha Intelligence Capital, OTB VenturesStrategic collaboration with Bristol Myers Squibb (incl. Series B-1 equity investment) · Jun 2022$80M · led by Bristol Myers SquibbOwkin—Mar 2019 → May 20202 rounds1 led—

IMInsilico Medicine$106.8MSep 2019 → Sep 20191 roundParticipant—

DateCompanyRoundRaisedValuationRoleEvidence

May 07, 2020OOwkinScienceOwkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical…$1Bvaluation$635.2MraisedRecent roundsTotal disclosed (company press kit aggregate) · null$304.1M · Bpifrance Large Ventures, Bristol-Myers Squibb +10Spin-out financing: Waiv (formerly Owkin Dx) · Mar 2026$33M · led by Alpha Intelligence Capital, OTB VenturesStrategic collaboration with Bristol Myers Squibb (incl. Series B-1 equity investment) · Jun 2022$80M · led by Bristol Myers SquibbOwkinSeries A extension / fresh financing$25M—Participant

Source ↗+1 ↗

Sep 10, 2019IMInsilico MedicineSeries B$37M$106.8MParticipant

Source ↗

Mar 07, 2019OOwkinScienceOwkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical…$1Bvaluation$635.2MraisedRecent roundsTotal disclosed (company press kit aggregate) · null$304.1M · Bpifrance Large Ventures, Bristol-Myers Squibb +10Spin-out financing: Waiv (formerly Owkin Dx) · Mar 2026$33M · led by Alpha Intelligence Capital, OTB VenturesStrategic collaboration with Bristol Myers Squibb (incl. Series B-1 equity investment) · Jun 2022$80M · led by Bristol Myers SquibbOwkinSeries A (venture round / extension)——Lead

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Sep 10, 2019IMInsilico MedicineSeries B$37M$106.8MParticipant

Source ↗

Source ↗+1 ↗

Source ↗